According to a recent report, shares in diabetes drug company Amylin Pharmaceuticals Inc soared this week following strong and positive support for their new diabetes drug .
The drug, which was supported by expert analysts in the US as likely to be one of the most effective on the market, has been in development for some time. A PiperJaffray analyst, Thomas Wei, was reported in the news as commenting that new Amylin drug Exenatide (LAR) will become the most effective on the market, superseding other diabetic drugs.
In response to the blessing, shares in Amylin climbed considerably, as many experts throughout America gave the thumbs up on the new drug. However, the diabetes medication will have strong competition in the form of Novo Nordisk alternative liraglutide.
The drug market for diabetics is an extremely competitive global industry.

Get our free newsletters

Stay up to date with the latest news, research and breakthroughs.

You May Also Like

Type 2 diabetes found to be a ‘significant risk factor’ among stroke victims

More evidence has been published which supports that diabetes is a “significant…

Top diabetes professor drafts risk assessment document for frontline COVID-19 staff

The health and wellbeing of frontline NHS staff has been prioritised among…

Conversation about doctors’ appointments occurring virtually rumbles on

More than half of GP appointments are still being delivered remotely in…